-
Mitomycin C Workflows for Cancer Research
2026-09-27
Use Mitomycin C to probe DNA damage responses and apoptosis, or to test whether cancer cells become more responsive to TRAIL. This guide connects practical dosing and solubility choices to a BAF53a glioma study while clearly separating established findings from experiments that still require validation.
-
EPI-001: An AR N-Terminal Domain Inhibitor
2026-09-26
EPI-001 lets researchers interrogate androgen receptor activity through its N-terminal domain, including signaling that may persist when the ligand-binding domain is absent. This workflow connects established prostate cancer models with a promising, still exploratory TNBC application, and pairs migration readouts with molecular checks to help separate pathway effects from general toxicity.
-
10074-G5 in Cell Viability and c-Myc Assays
2026-09-25
A practical guide to using 10074-G5 (SKU C5722) in c-Myc-focused viability, proliferation, and cytotoxicity experiments. It connects reported potency data with assay controls, solvent handling, interpretation limits, and a transparent approach to product selection.
-
Alfuzosin HCl in BPH Research: Practical Workflows
2026-09-25
Build reproducible studies of α1-adrenergic receptor signaling and lower urinary tract smooth muscle relaxation with a workflow tailored to Alfuzosin HCl. Practical assay guidance covers receptor and tissue models, solution handling, formulation testing, and how to interpret results without confusing symptom-relief research with antibacterial activity.
-
Cabazitaxel (XRP6258): Practical Research Workflow
2026-09-24
Cabazitaxel (XRP6258) is a taxoid compound for investigating microtubule dynamics disruption and antiproliferative responses, including in taxane-resistant cell models. It is water-insoluble, so use a validated DMSO- or ethanol-based preparation with matched vehicle controls; do not assume an aqueous stock or long-term solution stability.
-
4-Hydroxytamoxifen: Practical Workflow and QC
2026-09-24
4-Hydroxytamoxifen (4-OHT) is a DMSO-compatible estrogen receptor modulator for controlled cell-based and selected animal research workflows. It is not suitable for direct water- or ethanol-based preparation; define dose and vehicle controls in a pilot because the product information does not specify a universal working concentration or treatment schedule.
-
Cyclophosphamide: From Mechanism to Translation
2026-09-23
Cyclophosphamide can connect tumor-cell killing with immune modulation—but its hepatic activation and context-dependent effects demand careful model design. This guide translates its mechanism, protocol considerations, and a cross-domain lesson from neutropenic infection research into practical decisions for translational teams.
-
Danazol Research Workflows and Model Insights
2026-09-23
Danazol enables controlled investigation of androgen receptor signaling, steroidogenesis, and hypothalamic–pituitary–gonadal axis regulation. This practical guide connects cell-based assays with a recently reported rat model of precocious puberty and provides preparation, workflow, and troubleshooting strategies.
-
Niclosamide: From STAT3 Mechanism to Translation
2026-09-22
A mechanism-first guide to using Niclosamide in cancer research, integrating STAT3 biology, apoptosis and cell-cycle readouts, assay design, formulation control, and translational interpretation.
-
AZD2461: PARP Assays for Drug-Resistance Research
2026-09-22
AZD2461 helps researchers connect PARP-1 target engagement with cytotoxicity, G2-phase arrest, and resistance phenotypes in breast cancer models. This workflow emphasizes paired viability and cell-death measurements so investigators can distinguish growth inhibition from true killing and evaluate Pgp-related resistance more rigorously.
-
Drug Response Metrics in Cancer In Vitro
2026-09-21
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of anticancer drug response. The framework provides a practical basis for combining time-resolved viability measurements with direct death and apoptosis assays in cancer research.
-
Q-VD-OPh for Apoptosis Research Workflows
2026-09-21
Q-VD-OPh is a cell-permeable pan-caspase inhibitor for separating upstream mitochondrial commitment from downstream protease execution. This guide shows how to deploy it in BAK-activation assays, neurodegeneration models, and post-thaw viability workflows while avoiding common interpretation and formulation errors.
-
Perifosine and the Translational Logic of Akt
2026-09-20
Perifosine, also known as KRX-0401, offers a useful framework for linking Akt biology to apoptosis, radiation sensitization, and context-dependent translational decisions. This thought-leadership analysis connects cancer-focused Akt inhibition with the PI3K/Akt/mTOR findings reported in cerebral ischemia research while clarifying the boundaries of that cross-domain comparison.
-
Niclosamide: STAT3 Inhibitor Research Guide
2026-09-19
Niclosamide is a small-molecule STAT3 signaling pathway inhibitor identified as 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide. Product information reports a 0.7 μM IC50, inhibition of STAT3 Tyr-705 phosphorylation, and activity in prostate cancer and HL-60 xenograft models. This guide connects those findings with assay design, endpoint selection, and evidence limits.
-
XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum
2026-09-18
A 2026 Hematology study shows that selinexor-mediated XPO1 inhibition can increase cisplatin and oxaliplatin sensitivity in diffuse large B-cell lymphoma, with particularly strong combination effects in germinal-center B-cell-like disease. The work links enhanced cytotoxicity to apoptosis, reactive oxygen species accumulation, DNA-damage signaling, and coordinated changes in AKT/mTOR and JNK/ATM/p53 pathways.